Skip to main content
. 2022 Apr 8;5(4):e226136. doi: 10.1001/jamanetworkopen.2022.6136

Table 3. Adverse Events.

Adverse event No. (%)
Gram stain–guided group (n = 103) Guideline-based group (n = 103)
Kidney impairment 17 (16.5) 19 (18.4)
Thrombocytopenia
Moderate 12 (11.7) 4 (3.9)
Severe 4 (3.9) 7 (6.8)
Diarrhea 27 (26.2) 38 (36.9)
Clostridioides difficile infection 1 (1.0) 3 (2.9)
Skin rash 3 (2.9) 3 (2.9)
Seizure 5 (4.9) 5 (4.9)